This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sepracor Beats Back Naysayers

Shares of Sepracor (SEPR) soared Tuesday after the company issued fourth-quarter financial results that bulldozed Wall Street's expectations and enabled the company to enjoy its first profitable year.

The Marlborough, Mass., maker of the sleep drug Lunesta and the asthma medication Xopenex issued 2006 earnings and revenue guidance that exceeded the consensus prediction among analysts.

By early afternoon, Sepracor's stock was up $7.12, or 14.7%, to $55.50 on trading that was eight times the average daily volume for the past three months. The stock rose as high as $55.89.

Sepracor reported a fourth-quarter profit of $37.2 million, or 32 cents a share, on revenue of $311.1 million. Analysts polled by Thomson First Call expected a profit of 5 cents a share on revenue of $282.9 million. For the same period last year, Sepracor lost $33.7 million, or 33 cents a share, on revenue of $131.4 million.

The fourth-quarter results sent the full year into the black. Sepracor earned $4.97 million, or 4 cents a share, on revenue of $820.9 million last year. The consensus estimate called for a full-year loss of 42 cents a share on revenue of $793.7 million.

"This should silence the multitude of bears," says Corey Davis of J.P. Morgan, who reaffirmed his overweight rating on the stock. Lunesta produced fourth-quarter sales of $144.9 million, and Xopenex contributed $158 million, both of which exceeded Davis's expectations.

"We think there's plenty of upside here, given the recent surges in both market growth and share gains," says Davis, who doesn't own shares and whose firm has provided non-investment-banking services in the past 12 months.

The bearish case is that Sepracor can't sustain the necessary growth in Lunesta prescriptions and sales while it spends heavily to promote the drug against bigger, deeper-pocketed opponents. Competitors include Sanofi-Aventis (SNY), which sells Ambien and Ambien CR, and Takeda Pharmaceuticals, the maker of Rozerem.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AAPL $124.53 0.00%
FB $85.80 0.00%
GOOG $521.52 0.00%
TSLA $262.02 0.00%
YHOO $38.91 0.00%

Markets

DOW 17,596.35 -350.33 -1.95%
S&P 500 2,057.64 -43.85 -2.09%
NASDAQ 4,958.4680 -122.0370 -2.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs